Skip to main content
Erschienen in: Journal of Nuclear Cardiology 5/2022

16.07.2021 | Original Article

Effects of mineralocorticoid receptor antagonist eplerenone on cardiac sympathetic nerve activity and left ventricular remodeling after reperfusion therapy in patients with first ST-segment elevation myocardial infarction

verfasst von: Kazuyoshi Toda, MD, Shu Kasama, MD, Takuji Toyama, MD, Masato Kasahara, MD, Masahiko Kurabayashi, MD

Erschienen in: Journal of Nuclear Cardiology | Ausgabe 5/2022

Einloggen, um Zugang zu erhalten

Abstract

Purpose

The activation of the renin-angiotensin-aldosterone system prevents the uptake of norepinephrine and promotes structural remodeling of the heart. The mineralocorticoid receptor antagonist (MRA) eplerenone prevents left ventricular (LV) remodeling in patients with acute myocardial infarction, but its influence on cardiac sympathetic nerve activity (CSNA) has not been determined.

Methods

We retrospectively evaluated the first ST-segment elevation myocardial infarction (STEMI) patients in our database who underwent 123I-metaiodobenzylguanidine (MIBG) scintigraphy 3 weeks after admission. Eighty-four STEMI patients after primary coronary angioplasty were selected, and used propensity score matching to compare patients who treated with MRA (N = 42), and those who did not (N = 42). The LV end-diastolic volume, end-systolic volume, and ejection fraction were determined by echocardiography, and plasma procollagen type III amino terminal peptide (PIIINP) was measured before and 3 weeks after treatment. The delayed total defect score (TDS), delayed heart/mediastinum count (H/M) ratio, and washout rate (WR) were determined using 123I-MIBG scintigraphy after 3 weeks.

Results

Following primary angioplasty, age, gender, risk factors, culprit coronary artery, peak serum creatine phosphokinase concentration, and recanalization time were similar in the two groups. However, the MRA group showed significantly lower TDS and WR values (TDS: 22.8 ± 8.1 vs 32.2 ± 11.5, P < 0.005; WR: 31.1 ± 9.0% vs 42.7 ± 9.9%, P < 0.001) and a significantly higher H/M ratio (2.23 ± 0.41 vs 2.03 ± 0.36, P < 0.05) than the non-MRA group. The degree of change in LV parameters, and PIIINP were more favorable in the MRA group than in the non-MRA group. Moreover, multiple linear regression analyses revealed that both WR and not MRA treatment were significant predictor for LV remodeling, along with PIIINP concentrations.

Conclusion

Administration of eplerenone improves CSNA and prevents LV remodeling in patients with a first STEMI.
Literatur
1.
Zurück zum Zitat Pitt B, Remme W, Zannad F, Neaton J, Martinez F, Roniker B et al. Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study Investigators. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 2003;348:1309-21CrossRef Pitt B, Remme W, Zannad F, Neaton J, Martinez F, Roniker B et al. Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study Investigators. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 2003;348:1309-21CrossRef
2.
Zurück zum Zitat Leopold JA. Aldosterone, mineralocorticoid receptor activation, and cardiovascular remodeling. Circulation 2011;124:e466-e68CrossRef Leopold JA. Aldosterone, mineralocorticoid receptor activation, and cardiovascular remodeling. Circulation 2011;124:e466-e68CrossRef
3.
Zurück zum Zitat Weber KT, Brilla CG. Pathological hypertrophy and cardiac interstitium. Fibrosis and renin-angiotensin-aldosterone system. Circulation 1991;83:1849-65CrossRef Weber KT, Brilla CG. Pathological hypertrophy and cardiac interstitium. Fibrosis and renin-angiotensin-aldosterone system. Circulation 1991;83:1849-65CrossRef
4.
Zurück zum Zitat Buss SJ, Backs J, Kreusser MM, Hardt SE, Maser-Gluth C et al. Spironolactone preserves cardiac norepinephrine reuptake in salt-sensitive Dahl rats. Endocrinology 2006;147:2526-34CrossRef Buss SJ, Backs J, Kreusser MM, Hardt SE, Maser-Gluth C et al. Spironolactone preserves cardiac norepinephrine reuptake in salt-sensitive Dahl rats. Endocrinology 2006;147:2526-34CrossRef
5.
Zurück zum Zitat Iraqi W, Rossignol P, Angioi M, Fay R, Nuée J, Ketelslegers JM et al. Extracellular cardiac matrix biomarkers in patients with acute myocardial infarction complicated by left ventricular dysfunction and heart failure: insights from the Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study (EPHESUS). Circulation 2009;119:2471-79CrossRef Iraqi W, Rossignol P, Angioi M, Fay R, Nuée J, Ketelslegers JM et al. Extracellular cardiac matrix biomarkers in patients with acute myocardial infarction complicated by left ventricular dysfunction and heart failure: insights from the Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study (EPHESUS). Circulation 2009;119:2471-79CrossRef
6.
Zurück zum Zitat Sakata K, Mochizuki M, Yoshida H, Nawada R, Ohbayashi K, Ishikawa J et al. Cardiac sympathetic dysfunction contributes to left ventricular remodeling after acute myocardial infarction. Eur J Nucl Med 2000;27:1641-49CrossRef Sakata K, Mochizuki M, Yoshida H, Nawada R, Ohbayashi K, Ishikawa J et al. Cardiac sympathetic dysfunction contributes to left ventricular remodeling after acute myocardial infarction. Eur J Nucl Med 2000;27:1641-49CrossRef
7.
Zurück zum Zitat Matsunari I, Schricke U, Bengel FM, Haase HU, Barthel P, Schmidt G et al. Extent of cardiac sympathetic neuronal damage is determined by the area of ischemia in patients with acute coronary syndromes. Circulation 2000;101:2579-85CrossRef Matsunari I, Schricke U, Bengel FM, Haase HU, Barthel P, Schmidt G et al. Extent of cardiac sympathetic neuronal damage is determined by the area of ischemia in patients with acute coronary syndromes. Circulation 2000;101:2579-85CrossRef
8.
Zurück zum Zitat Kasama S, Toyama T, Sumino H, Kumakura H, Takayama Y, Minami K et al. Prognostic value of cardiac sympathetic nerve activity evaluated by [123I]m-iodobenzylguanidine imaging in patients with ST-segment elevation myocardial infarction. Heart 2011;97:20-26CrossRef Kasama S, Toyama T, Sumino H, Kumakura H, Takayama Y, Minami K et al. Prognostic value of cardiac sympathetic nerve activity evaluated by [123I]m-iodobenzylguanidine imaging in patients with ST-segment elevation myocardial infarction. Heart 2011;97:20-26CrossRef
9.
Zurück zum Zitat Yee KM, Pringle SD, Struthers AD. Circadian variation in the effects of aldosterone blockade on heart rate variability and QT dispersion in congestive heart failure. J Am Coll Cardiol 2001;37:1800-07CrossRef Yee KM, Pringle SD, Struthers AD. Circadian variation in the effects of aldosterone blockade on heart rate variability and QT dispersion in congestive heart failure. J Am Coll Cardiol 2001;37:1800-07CrossRef
10.
Zurück zum Zitat Huang BS, White RA, Jeng AY, Leenen FH. Role of central nervous system aldosterone synthase and mineralocorticoid receptors in salt-induced hypertension in Dahl salt-sensitive rats. Am J Physiol Regul Integr Comp Physiol 2009;296:R994-R00CrossRef Huang BS, White RA, Jeng AY, Leenen FH. Role of central nervous system aldosterone synthase and mineralocorticoid receptors in salt-induced hypertension in Dahl salt-sensitive rats. Am J Physiol Regul Integr Comp Physiol 2009;296:R994-R00CrossRef
11.
Zurück zum Zitat Jacobson AF, White S, Travin MI, Tseng C. Impact of concomitant medication use on myocardial 123I-mIBG imaging results in patients with heart failure. Nucl Med Commun 2017;38:141-48CrossRef Jacobson AF, White S, Travin MI, Tseng C. Impact of concomitant medication use on myocardial 123I-mIBG imaging results in patients with heart failure. Nucl Med Commun 2017;38:141-48CrossRef
12.
Zurück zum Zitat Kasama S, Toyama T, Kumakura H, Takayama Y, Ichikawa S, Suzuki T et al. Effects of candesartan on cardiac sympathetic nerve activity in patients with congestive heart failure and preserved left ventricular ejection fraction. J Am Coll Cardiol 2005;45:661-67CrossRef Kasama S, Toyama T, Kumakura H, Takayama Y, Ichikawa S, Suzuki T et al. Effects of candesartan on cardiac sympathetic nerve activity in patients with congestive heart failure and preserved left ventricular ejection fraction. J Am Coll Cardiol 2005;45:661-67CrossRef
13.
Zurück zum Zitat Kasama S, Toyama T, Kumakura H, Takayama Y, Ichikawa S, Suzuki T et al. Effects of intravenous atrial natriuretic peptide on cardiac sympathetic nerve activity and left ventricular remodeling in patients with first anterior acute myocardial infarction. J Am Coll Cardiol 2007;49:667-74CrossRef Kasama S, Toyama T, Kumakura H, Takayama Y, Ichikawa S, Suzuki T et al. Effects of intravenous atrial natriuretic peptide on cardiac sympathetic nerve activity and left ventricular remodeling in patients with first anterior acute myocardial infarction. J Am Coll Cardiol 2007;49:667-74CrossRef
14.
Zurück zum Zitat Kasama S, Toyama T, Hatori T, Sumino H, Kumakura H, Takayama Y et al. Evaluation of cardiac sympathetic nerve activity and left ventricular remodeling in patients with dilated cardiomyopathy on the treatment containing carvedilol. Eur Heart J 2007;28:989-95CrossRef Kasama S, Toyama T, Hatori T, Sumino H, Kumakura H, Takayama Y et al. Evaluation of cardiac sympathetic nerve activity and left ventricular remodeling in patients with dilated cardiomyopathy on the treatment containing carvedilol. Eur Heart J 2007;28:989-95CrossRef
15.
Zurück zum Zitat Cerqueira MD, Weissman NJ, Dilsizian V, Jacobs AK, Kaul S, Laskey WK et al. Standardized myocardial segmentation and nomenclature for tomographic imaging of the heart: A statement for healthcare professionals from the Cardiac Imaging Committee of the Council on Clinical Cardiology of the American Heart Association. Circulation 2002;105:539-42CrossRef Cerqueira MD, Weissman NJ, Dilsizian V, Jacobs AK, Kaul S, Laskey WK et al. Standardized myocardial segmentation and nomenclature for tomographic imaging of the heart: A statement for healthcare professionals from the Cardiac Imaging Committee of the Council on Clinical Cardiology of the American Heart Association. Circulation 2002;105:539-42CrossRef
16.
Zurück zum Zitat Schiller NB, Shah PM, Crawford M, DeMaria A, Devereux R, Feigenbaum H et al. Recommendations for quantitation of the left ventricle by two-dimensional echocardiography. American Society of Echocardiography Committee on Standards, Subcommittee on Quantitation of Two-Dimensional Echocardiograms. J Am Soc Echocardiogr 1989;2:358-67CrossRef Schiller NB, Shah PM, Crawford M, DeMaria A, Devereux R, Feigenbaum H et al. Recommendations for quantitation of the left ventricle by two-dimensional echocardiography. American Society of Echocardiography Committee on Standards, Subcommittee on Quantitation of Two-Dimensional Echocardiograms. J Am Soc Echocardiogr 1989;2:358-67CrossRef
17.
Zurück zum Zitat Kasama S, Toyama T, Sumino H, Kumakura H, Takayama Y, Ichikawa S et al. Long-term nicorandil therapy improves cardiac sympathetic nerve activity after reperfusion therapy in patients with first acute myocardial infarction. J Nucl Med 2007;48:1676-82CrossRef Kasama S, Toyama T, Sumino H, Kumakura H, Takayama Y, Ichikawa S et al. Long-term nicorandil therapy improves cardiac sympathetic nerve activity after reperfusion therapy in patients with first acute myocardial infarction. J Nucl Med 2007;48:1676-82CrossRef
18.
Zurück zum Zitat Kasama S, Toyama T, Sumino H, Kumakura H, Takayama Y, Minami K et al. Effects of spironolactone on cardiac sympathetic nerve activity and left ventricular remodelling after reperfusion therapy in patients with first ST-segment elevation myocardial infarction. Heart 2011;97:817-22CrossRef Kasama S, Toyama T, Sumino H, Kumakura H, Takayama Y, Minami K et al. Effects of spironolactone on cardiac sympathetic nerve activity and left ventricular remodelling after reperfusion therapy in patients with first ST-segment elevation myocardial infarction. Heart 2011;97:817-22CrossRef
19.
Zurück zum Zitat Luellen JK, Shadish WR, Clark MH. Propensity scores: An introduction and experimental test. Eval Rev 2005;29:530-58CrossRef Luellen JK, Shadish WR, Clark MH. Propensity scores: An introduction and experimental test. Eval Rev 2005;29:530-58CrossRef
20.
Zurück zum Zitat Wang W. Chronic administration of aldosterone depresses baroreceptor reflex function in the dog. Hypertension 1994;24:571-75CrossRef Wang W. Chronic administration of aldosterone depresses baroreceptor reflex function in the dog. Hypertension 1994;24:571-75CrossRef
21.
Zurück zum Zitat Rocha R, Chander PN, Khanna K, Zuckerman A, Stier CT Jr. Mineralocorticoid blockade reduces vascular injury in stroke-prone hypertensive rats. Hypertension 1998;31:451-58CrossRef Rocha R, Chander PN, Khanna K, Zuckerman A, Stier CT Jr. Mineralocorticoid blockade reduces vascular injury in stroke-prone hypertensive rats. Hypertension 1998;31:451-58CrossRef
22.
Zurück zum Zitat Yoshimura M, Nakamura S, Ito T, Nakayama M, Harada E, Mizuno Y et al. Expression of aldosterone synthase gene in failing human heart: Quantitative analysis using modified real-time polymerase chain reaction. J Clin Endocrinol Metab 2002;87:3936-40CrossRef Yoshimura M, Nakamura S, Ito T, Nakayama M, Harada E, Mizuno Y et al. Expression of aldosterone synthase gene in failing human heart: Quantitative analysis using modified real-time polymerase chain reaction. J Clin Endocrinol Metab 2002;87:3936-40CrossRef
23.
Zurück zum Zitat Mizuno Y, Yoshimura M, Yasue H, Sakamoto T, Ogawa H, Kugiyama K et al. Aldosterone production is activated in failing ventricle in humans. Circulation 2001;103:72-77CrossRef Mizuno Y, Yoshimura M, Yasue H, Sakamoto T, Ogawa H, Kugiyama K et al. Aldosterone production is activated in failing ventricle in humans. Circulation 2001;103:72-77CrossRef
24.
Zurück zum Zitat Harada E, Yoshimura M, Yasue H, Nakagawa O, Nakagawa M, Harada M et al. Aldosterone induces angiotensin-converting-enzyme gene expression in cultured neonatal rat cardiocytes. Circulation 2001;104:137-39CrossRef Harada E, Yoshimura M, Yasue H, Nakagawa O, Nakagawa M, Harada M et al. Aldosterone induces angiotensin-converting-enzyme gene expression in cultured neonatal rat cardiocytes. Circulation 2001;104:137-39CrossRef
25.
Zurück zum Zitat Wieland DM, Wu J, Brown LE, Mangner TJ, Swanson DP, Beierwaltes WH. Radiolabeled adrenergic neuron-blocking agents: Adrenomedullary imaging with [131I]iodobenzylguanidine. J Nucl Med 1980;21:349-53PubMed Wieland DM, Wu J, Brown LE, Mangner TJ, Swanson DP, Beierwaltes WH. Radiolabeled adrenergic neuron-blocking agents: Adrenomedullary imaging with [131I]iodobenzylguanidine. J Nucl Med 1980;21:349-53PubMed
26.
Zurück zum Zitat Schofer J, Spielmann R, Schuchert A, Weber K, Schluter M. Iodine-123 meta-iodobenzylguanidine scintigraphy: A noninvasive method to demonstrate myocardial adrenergic nervous system disintegrity in patients with idiopathic dilated cardiomyopathy. J Am Coll Cardiol 1988;12:1252-58CrossRef Schofer J, Spielmann R, Schuchert A, Weber K, Schluter M. Iodine-123 meta-iodobenzylguanidine scintigraphy: A noninvasive method to demonstrate myocardial adrenergic nervous system disintegrity in patients with idiopathic dilated cardiomyopathy. J Am Coll Cardiol 1988;12:1252-58CrossRef
27.
Zurück zum Zitat Takeishi Y, Atsumi H, Fujiwara S, Takahashi K, Tomoike H. ACE inhibition reduces cardiac iodine-123-MIBG release in heart failure. J Nucl Med 1997;38:1085-89PubMed Takeishi Y, Atsumi H, Fujiwara S, Takahashi K, Tomoike H. ACE inhibition reduces cardiac iodine-123-MIBG release in heart failure. J Nucl Med 1997;38:1085-89PubMed
28.
Zurück zum Zitat Toyama T, Aihara Y, Iwasaki T, Hasegawa A, Suzuki T, Nagai R et al. Cardiac sympathetic activity estimated by 123I-MIBG myocardial imaging in patients with dilated cardiomyopathy after beta-blocker or angiotensin-converting enzyme inhibitor therapy. J Nucl Med 1999;40:217-23PubMed Toyama T, Aihara Y, Iwasaki T, Hasegawa A, Suzuki T, Nagai R et al. Cardiac sympathetic activity estimated by 123I-MIBG myocardial imaging in patients with dilated cardiomyopathy after beta-blocker or angiotensin-converting enzyme inhibitor therapy. J Nucl Med 1999;40:217-23PubMed
29.
Zurück zum Zitat Kasama S, Toyama T, Kumakura H, Takayama Y, Ichikawa S, Suzuki T et al. Addition of valsartan to an angiotensin-converting enzyme inhibitor improves cardiac sympathetic nerve activity and left ventricular function in patients with congestive heart failure. J Nucl Med 2003;44:884-90PubMed Kasama S, Toyama T, Kumakura H, Takayama Y, Ichikawa S, Suzuki T et al. Addition of valsartan to an angiotensin-converting enzyme inhibitor improves cardiac sympathetic nerve activity and left ventricular function in patients with congestive heart failure. J Nucl Med 2003;44:884-90PubMed
30.
Zurück zum Zitat Kasama S, Toyama T, Kumakura H, Takayama Y, Ichikawa S, Suzuki T et al. Effect of spironolactone on cardiac sympathetic nerve activity and left ventricular 12remodeling in patients with dilated cardiomyopathy. J Am Coll Cardiol 2003;41:574-81CrossRef Kasama S, Toyama T, Kumakura H, Takayama Y, Ichikawa S, Suzuki T et al. Effect of spironolactone on cardiac sympathetic nerve activity and left ventricular 12remodeling in patients with dilated cardiomyopathy. J Am Coll Cardiol 2003;41:574-81CrossRef
31.
Zurück zum Zitat Kasama S, Toyama T, Sumino H, Kumakura H, Takayama Y, Minami K et al. Effects of mineralocorticoid receptor antagonist spironolactone on cardiac sympathetic nerve activity and prognosis in patients with chronic heart failure. Int J Cardiol 2013;167:244-49CrossRef Kasama S, Toyama T, Sumino H, Kumakura H, Takayama Y, Minami K et al. Effects of mineralocorticoid receptor antagonist spironolactone on cardiac sympathetic nerve activity and prognosis in patients with chronic heart failure. Int J Cardiol 2013;167:244-49CrossRef
32.
Zurück zum Zitat Aikawa T, Naya M, Obara M, Oyama-Manabe N, Manabe O, Magota K et al. Regional interaction between myocardial sympathetic denervation, contractile dysfunction, and fibrosis in heart failure with preserved ejection fraction: 11C-hydroxyephedrine PET study. Eur J Nucl Med Mol Imaging 2017;44:1897-05CrossRef Aikawa T, Naya M, Obara M, Oyama-Manabe N, Manabe O, Magota K et al. Regional interaction between myocardial sympathetic denervation, contractile dysfunction, and fibrosis in heart failure with preserved ejection fraction: 11C-hydroxyephedrine PET study. Eur J Nucl Med Mol Imaging 2017;44:1897-05CrossRef
33.
Zurück zum Zitat Kramer CM, Nicol PD, Rogers WJ, Suzuki MM, Shaffer A, Theobald TM et al. Reduced sympathetic innervation underlies adjacent noninfarcted region dysfunction during left ventricular remodeling. J Am Coll Cardiol 1997;30:1079-85CrossRef Kramer CM, Nicol PD, Rogers WJ, Suzuki MM, Shaffer A, Theobald TM et al. Reduced sympathetic innervation underlies adjacent noninfarcted region dysfunction during left ventricular remodeling. J Am Coll Cardiol 1997;30:1079-85CrossRef
34.
Zurück zum Zitat Klappacher G, Franzen P, Haab D, Mehrabi M, Binder M, Plesch K et al. Measuring extracellular matrix turnover in the serum of patients with idiopathic or ischemic dilated cardiomyopathy and impact on diagnosis and prognosis. Am J Cardiol 1995;75:913-18CrossRef Klappacher G, Franzen P, Haab D, Mehrabi M, Binder M, Plesch K et al. Measuring extracellular matrix turnover in the serum of patients with idiopathic or ischemic dilated cardiomyopathy and impact on diagnosis and prognosis. Am J Cardiol 1995;75:913-18CrossRef
35.
Zurück zum Zitat Host NB, Jensen LT, Bendixen PM, Jensen SE, Koldkjaer OG, Simonsen EE. The aminoterminal propeptide of type III procollagen provides new information on prognosis after acute myocardial infarction. Am J Cardiol 1995;76:869-73CrossRef Host NB, Jensen LT, Bendixen PM, Jensen SE, Koldkjaer OG, Simonsen EE. The aminoterminal propeptide of type III procollagen provides new information on prognosis after acute myocardial infarction. Am J Cardiol 1995;76:869-73CrossRef
36.
Zurück zum Zitat Bolognese L, Neskovic AN, Parodi G, Cerisano G, Buonamici P, Santoro GM et al. Left ventricular remodeling after primary coronary angioplasty: Patterns of left ventricular dilation and long-term prognostic implications. Circulation 2002;106:2351-57CrossRef Bolognese L, Neskovic AN, Parodi G, Cerisano G, Buonamici P, Santoro GM et al. Left ventricular remodeling after primary coronary angioplasty: Patterns of left ventricular dilation and long-term prognostic implications. Circulation 2002;106:2351-57CrossRef
37.
Zurück zum Zitat Hayashi M, Tsutamoto T, Wada A, Tsutsui T, Ishii C, Ohno K et al. Immediate administration of mineralocorticoid receptor antagonist spironolactone prevents post-infarct left ventricular remodeling associated with suppression of a marker of myocardial collagen synthesis in patients with first anterior acute myocardial infarction. Circulation 2003;107:2559-65CrossRef Hayashi M, Tsutamoto T, Wada A, Tsutsui T, Ishii C, Ohno K et al. Immediate administration of mineralocorticoid receptor antagonist spironolactone prevents post-infarct left ventricular remodeling associated with suppression of a marker of myocardial collagen synthesis in patients with first anterior acute myocardial infarction. Circulation 2003;107:2559-65CrossRef
38.
Zurück zum Zitat Jacobson AF, Senior R, Cerqueira MD, Wong ND, Thomas GS, Lopez VA et al. Myocardial iodine-123 meta-iodobenzylguanidine imaging and cardiac events in heart failure. Results of the prospective ADMIRE-HF (AdreView Myocardial Imaging for Risk Evaluation in Heart Failure) study. J Am Coll Cardiol 2010;55:2212–21CrossRef Jacobson AF, Senior R, Cerqueira MD, Wong ND, Thomas GS, Lopez VA et al. Myocardial iodine-123 meta-iodobenzylguanidine imaging and cardiac events in heart failure. Results of the prospective ADMIRE-HF (AdreView Myocardial Imaging for Risk Evaluation in Heart Failure) study. J Am Coll Cardiol 2010;55:2212–21CrossRef
Metadaten
Titel
Effects of mineralocorticoid receptor antagonist eplerenone on cardiac sympathetic nerve activity and left ventricular remodeling after reperfusion therapy in patients with first ST-segment elevation myocardial infarction
verfasst von
Kazuyoshi Toda, MD
Shu Kasama, MD
Takuji Toyama, MD
Masato Kasahara, MD
Masahiko Kurabayashi, MD
Publikationsdatum
16.07.2021
Verlag
Springer International Publishing
Erschienen in
Journal of Nuclear Cardiology / Ausgabe 5/2022
Print ISSN: 1071-3581
Elektronische ISSN: 1532-6551
DOI
https://doi.org/10.1007/s12350-021-02733-4

Weitere Artikel der Ausgabe 5/2022

Journal of Nuclear Cardiology 5/2022 Zur Ausgabe

„Jeder Fall von plötzlichem Tod muss obduziert werden!“

17.05.2024 Plötzlicher Herztod Nachrichten

Ein signifikanter Anteil der Fälle von plötzlichem Herztod ist genetisch bedingt. Um ihre Verwandten vor diesem Schicksal zu bewahren, sollten jüngere Personen, die plötzlich unerwartet versterben, ausnahmslos einer Autopsie unterzogen werden.

Hirnblutung unter DOAK und VKA ähnlich bedrohlich

17.05.2024 Direkte orale Antikoagulanzien Nachrichten

Kommt es zu einer nichttraumatischen Hirnblutung, spielt es keine große Rolle, ob die Betroffenen zuvor direkt wirksame orale Antikoagulanzien oder Marcumar bekommen haben: Die Prognose ist ähnlich schlecht.

Schlechtere Vorhofflimmern-Prognose bei kleinem linken Ventrikel

17.05.2024 Vorhofflimmern Nachrichten

Nicht nur ein vergrößerter, sondern auch ein kleiner linker Ventrikel ist bei Vorhofflimmern mit einer erhöhten Komplikationsrate assoziiert. Der Zusammenhang besteht nach Daten aus China unabhängig von anderen Risikofaktoren.

Semaglutid bei Herzinsuffizienz: Wie erklärt sich die Wirksamkeit?

17.05.2024 Herzinsuffizienz Nachrichten

Bei adipösen Patienten mit Herzinsuffizienz des HFpEF-Phänotyps ist Semaglutid von symptomatischem Nutzen. Resultiert dieser Benefit allein aus der Gewichtsreduktion oder auch aus spezifischen Effekten auf die Herzinsuffizienz-Pathogenese? Eine neue Analyse gibt Aufschluss.

Update Kardiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.